因果机器学习估算COPD急性加重个体化治疗效果
本研究利用SUMMIT试验8151例COPD患者数据,开发因果森林模型估算FF/VI对比安慰剂的个体化治疗效果,并在IMPACT试验5990例中验证FF/UMEC/VI对比UMEC/VI的效果。两个试验中预测效果最强的患者分位数均显示观察到的急性加重率最大降幅(0.54和0.53,p<0.001)。肺功能差和血嗜酸粒细胞分别是各自试验中最强的个体化效果预测因子。
要点
- 因果森林模型可在随机对照试验数据中估算COPD治疗的个体化效果。
- 预测效果最强的患者分位数观察到急性加重率最大降幅(0.54和0.53)。
- 肺功能差和血嗜酸粒细胞分别是SUMMIT和IMPACT中最强的效果预测因子。
核心结论
- 基于随机对照试验数据的因果机器学习模型可识别COPD患者对不同治疗的个体化反应并揭示治疗特征。
研究设计与样本
- 利用SUMMIT试验8151例COPD患者数据开发因果森林模型,估算FF/VI对比安慰剂对年急性加重率的效果。
- 在IMPACT试验5990例受试者中验证方法,估算FF/UMEC/VI对比UMEC/VI对急性加重率的效果。
主要发现
- SUMMIT中模型在训练集5705例优化、2446例测试,Q-score为0.61。
- IMPACT中模型在训练集4193例优化、1797例测试,Q-score为0.21。
- 两个试验中预测效果最强的患者分位数均显示观察到的急性加重率最大降幅(0.54和0.53,p<0.001)。
- SUMMIT中肺功能差是最强的个体化效果预测因子,IMPACT中血嗜酸粒细胞是最强预测因子。
临床怎么用
- 此类模型有望成为COPD个体化治疗决策的临床有用工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Estimating the causal effect of an intervention at individual level, also called individual treatment effect (ITE), may help in identifying response prior to the intervention. OBJECTIVES: We aimed to develop machine learning (ML) models which estimate ITE of an intervention using data from randomised controlled trials and illustrate this approach with prediction of ITE on annual chronic obstructive pulmonary disease (COPD) exacerbation rates. METHODS: We used data from 8151 patients with COPD of the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) trial (NCT01313676) to address the ITE of fluticasone furoate/vilanterol (FF/VI) versus control (placebo) on exacerbation rate and developed a novel metric, Q-score, for assessing the power of causal inference models. We then validated the methodology on 5990 subjects from the InforMing the PAthway of COPD Treatment (IMPACT) trial (NCT02164513) to estimate the ITE of FF/umeclidinium/VI (FF/UMEC/VI) versus UMEC/VI on exacerbation rate. We used Causal Forest as causal inference model. RESULTS: In SUMMIT, Causal Forest was optimised on the training set (n=5705) and tested on 2446 subjects (Q-score 0.61). In IMPACT, Causal Forest was optimised on 4193 subjects in the training set and tested on 1797 individuals (Q-score 0.21). In both trials, the quantiles of patients with the strongest ITE consistently demonstrated the largest reductions in observed exacerbations rates (0.54 and 0.53, p<0.001). Poor lung function and blood eosinophils, respectively, were the strongest predictors of ITE. CONCLUSIONS: This study shows that ML models for causal inference can be used to identify individual response to different COPD treatments and highlight treatment traits. Such models could become clinically useful tools for individual treatment decisions in COPD.
引用
- Verstraete, Gyselinck, Huts, et al. Estimating individual treatment effects on COPD exacerbations by causal machine learning on randomised controlled trials. Thorax. 2023. PMID: 37012070. doi:10.1136/thorax-2022-219382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。